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Abstract Women with an increased lifetime risk of
ovarian cancer are advised to undergo risk-reducing salp-
ingo-oophorectomy (RRSO) to reduce risk of adnexal
cancer. We investigated the uptake of RRSO and evaluated
the influence of personal medical history of (breast) cancer,
risk-reducing mastectomy (RRM) and family history of
ovarian and/or breast cancer on the RRSO decision. This
single center retrospective observational cohort study was
performed in a tertiary multidisciplinary clinic for heredi-
tary cancer of the University Medical Centre Utrecht, the
Netherlands. Women C35 years old with an estimated
lifetime risk of ovarian cancer C10 %, who had completed
childbearing, were eligible for RRSO. Uptake and timing
of RRSO were analyzed. Influence of personal medical
history and family history on RRSO decision making, were
evaluated with logistic regression. The study population
consisted of 218 women (45.0 % BRCA1 mutation carrier,
28.0 % BRCA2 mutation carrier, 27.0 % with familial
susceptibility) with 87.2 % RRSO uptake. The median age
at RRSO was 44.5 (range 28–73) years. Of the women
undergoing RRSO, 78.3 % needed B3 consultations to
reach this decision. Multivariable analysis showed a sig-
nificant difference in RRSO uptake for women with a
history of RRM [OR 3.66 95 % CI (1.12–11.98)], but no
significant difference in women with a history of breast
cancer [OR 1.38 95 % CI (0.50–3.79)], nor with a family
history of ovarian and/or breast cancer [OR 1.10 95 % CI
(0.44–2.76)]. We conclude that RRSO counseling, without
the alternative of screening, is effective. The uptake is
increased in women with a history of RRM.
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Introduction
Women carrying a BRCA1 or BRCA2 gene mutation have
a life time risk of developing ovarian cancer of 31–58.9
and 6–34.5 % respectively [1–5]. Risk-reducing salpingo-
oophorectomy (RRSO) has been associated with a risk
reduction of 85–96 % for ovarian, fallopian tube and
peritoneal cancer [6–9]. A meta-analysis by Marchetti et al.
(2014), showed a hazard ratio of 0.19 (95 % CI 0.13–0.27)
for the development of ovarian cancer in BRCA1/2 muta-
tion carriers up to six years after RRSO [10]. A large meta-
analysis by Rebbeck et al. [11] showed a hazard ratio of
0.21 (95 % CI 0.12–0.39) for the development of ovarian
or breast cancer, up to five years after RRSO. Risk
reduction of breast cancer after RRSO was estimated to be
53–72 % in BRCA1/2 mutation carriers in several studies
[6–9]. A recent Dutch cohort study found no evidence for a
risk reduction of breast cancer risk in BRCA1/2 mutation
carriers after RRSO [hazard ratio 1.09 (95 % CI
0.67–1.77)] and stated that previous data may have over-
estimated the risk reduction because of bias [12].
Screening for ovarian cancer by determining CA125
protein serum levels and performing transvaginal ultra-
sonography, has proven to be neither reliable, nor
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beneficial in reducing the risk of ovarian cancer, nor does it
improve survival [13–19]. Therefore, RRSO is the only
scientifically proven strategy to reduce the risk of devel-
oping ovarian and fallopian tube cancer and it is recom-
mended to women with an increased lifetime risk [10, 11].
The Multidisciplinary Hereditary Cancer Clinic
(MHCC) of the UMC Utrecht aims to counsel and treat
women at increased lifetime risk of developing ovarian
cancer. This encompasses BRCA1/2 mutation carriers and
women with familial susceptibility to ovarian cancer,
which is determined by having a pedigree-based estimated
lifetime risk of C10 % [20]. When over 35 years of age
and having completed childbearing, these women become
eligible for RRSO [21]. During RRSO counseling, the
surgical risks as well as the benefits and indications for
Hormonal Replacement Therapy (HRT) after surgery, are
outlined. Screening is explicitly not offered as an alterna-
tive to RRSO. Psychosocial support is routinely offered in
the process of decision making.
Reported RRSO uptake in the literature varies from 10.9
to 75 % [22–34]. With our approach, we expect a high
RRSO uptake, since undergoing the surgery is the only
risk-reducing strategy.
There are demographic, medical and psychosocial fac-
tors that affect the decision making to undergo risk-re-
ducing surgery, including age, parity, menopausal status,
ethnicity, education level, idea of perceived risk, level of
anxiety or distress, etcetera [22, 23, 25–28, 30, 32–35].
Since BRCA1/2 mutation status and familial susceptibility
to ovarian cancer are familial conditions that concern close
relatives, it is assumed that decision making may be
influenced by personal experience and family perspectives
or experience with cancer within the family. Several
studies support this by showing an increase of RRSO
uptake with a more positive family history of breast and/or
ovarian cancer [23, 27, 29, 33]. However, others do not
report this [28].
Here, we explore the effect of a personal medical history
of breast cancer and risk-reducing mastectomy (RRM) as
well as family history of ovarian and/or breast cancer in the
decision making of undergoing RRSO for women with an
increased lifetime risk of ovarian cancer. Secondly, we
determined howmany consultations were needed for women
to decide to undergo RRSO. This insight is of importance, to
provide personally appropriate counseling to every patient.
Methods
MHCC and counseling
In this single center retrospective cohort study, we identi-
fied all women who visited the MHCC from January 2011
through June 2013. Genetic testing and pedigree-based risk
assessment were performed by the medical genetics
department. Carriers of a BRCA1 mutation are explained to
have a lifetime risk of ovarian cancer of 30–60 % and
BRCA2 mutation carriers of 5–20 %. RRSO is recom-
mended from age 35 years onwards (BRCA1 carrier) or
from 40 years onwards (BRCA2 carrier). Women with a
positive family history, but in whom genetic testing in an
affected relative could not be performed, or could not
identify a BRCA mutation (e.g. due to uninformative test
result), were defined as women with a familial suscepti-
bility to ovarian cancer. They are advised to undergo
RRSO when the estimated lifetime risk is C10 %.
In adherence to the Dutch guideline for treatment of
hereditary ovarian cancer, women were considered eligible
for RRSO with an estimated lifetime risk C10 % and if
they were C35 years of age and had completed child-
bearing [18]. They received counseling for RRSO from a
gynecologic oncologist and a nurse specialized in familial
cancer care. Counseling was aimed at informing patients
about the risks of the surgery, the induction of menopausal
status by the surgery and indications for HRT, the medical
and psychosocial support available, the risks of developing
ovarian and fallopian tube cancer and the reduction of this
risk by undergoing RRSO.
Study population
The study population consists of all women who received
counseling for RRSO, based on the criteria described pre-
viously. Women who had completed childbearing at
\35 years of age and had received counseling for RRSO
were included too.
Women previously diagnosed with ovarian cancer, car-
riers of a mutation in one of the MMR genes (predisposing
to Lynch syndrome), women with increased risk of breast
cancer or other non-breast and ovarian related hereditary
tumors only, were excluded.
Statistical analysis
Statistical analyses were carried out using the ‘Statistical
Package for the Social Sciences’ version 21.0 (SPSS,
International Business Machines, New York, United
States). Comparison of categorical variables was per-
formed by Chi square testing. The Mann–Whitney U test
was used for count data and continuous variables that were
not normally distributed. A p value of\0.05 was consid-
ered statistically significant.
Uni- and multivariable logistic regression, producing
odds ratios (OR), were used to model the explanatory
variables against the binary RRSO decision. Explanatory
variables of interest included the effect of personal medical
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history of breast cancer, any malignancy (excluding all
non-melanoma skin malignancies) and RRM. Furthermore,
family history of ovarian and/or breast cancer were ana-
lyzed according to the first or second/third degree in which
they occurred. Multiple imputations (m = 10) were used to
correct randomly missing values.
During the multivariable analysis, explanatory variables
were adjusted for mutation status, age, parity and meno-
pausal status, since these have been identified as significant




We identified 218 women who were considered eligible for
undergoing RRSO. As shown in Table 1, the majority
carried a BRCA1 or BRCA2 mutation (72.9 %).
In total, 190 women opted for RRSO, resulting in an
uptake of 87.2 %. Uptake was higher in BRCA1/2 muta-
tion carriers than in women with familial susceptibility to
ovarian cancer (90.6 and 78.0 % respectively).
Median age at RRSO was 44.5 (range 28–73). Median
ages at RRSO for BRCA1 mutation carriers, BRCA2
mutation carriers and women with familial susceptibility
were 42 (range 30–63), 47 (range 28–73) and 48 years
(range 31–65) respectively.
Number of consultations
We registered the number of consultations women had had
with the gynecologic oncologist before they decided to
undergo RRSO. It showed that 57.4 % of the women who
eventually underwent RRSO, had decided so at the first
consultation with the gynecologic oncologist or the spe-
cialized nurse. An additional 11.1 % had decided so by the
second consultation and an additional 5.3 % had made this
decision by the third consultation. The remaining 26.2 %
needed four or more consultations to make the decision.
Women with 1st degree relatives who had breast cancer
needed significantly less consultations todecide forRRSO, this
in contrast to having 1st degree relatives with ovarian cancer.
See Table 2 for the univariable analysis. After multivariable
adjustment, only a 1st degree relative with breast cancer
remained as a significant factor (p 0.01) with 1.51 (95 % CI
0.32–2.70) less consultations before the RRSO decision.
Personal and medical history
Table 3 shows the outcomes of univariable and multivari-
able analyses of RRSO uptake in women with family
history of ovarian and/or breast cancer or a personal history
of (breast) cancer.
Women who had previously been diagnosed with breast
cancer or any other type of cancer (excluding all non-me-
lanoma skin malignancies), did not have significantly
increased odds of undergoing a RRSO [OR 1.38; 95 %
confidence interval (CI) (0.50–3.79) and OR 1.60; 95 % CI
(0.59–4.37) respectively]. Women who had undergone
RRM were more likely to undergo RRSO, with an odds
ratio of 3.66; 95 % CI (1.12–11.98) in multivariable
analysis.
Table 1 Baseline characteristics of study-population n = 218
Mutation status, n (%)
BRCA1 98 (45.0 %)
BRCA2 61 (28.0 %)
Familial susceptibility 59 (27.0 %)
Age at first presentation
Median (range), years 43 (27–77)
Mean (Standard deviation), years 44.63 (±9.37)
Menopausal status at first presentation
Premenopausal, n (%) 126 (57.8 %)
Postmenopausal, n (%) 70 (32.1 %)
Unknown, n (%) 22 (10.1 %)
Parity, n (%)
0, n (%) 40 (18.3 %)
1, n (%) 22 (10.1 %)
2, n (%) 88 (40.4 %)
[2, n (%) 46 (21.1 %)
Unknown, n (%) 22 (10.1 %)
Medical history
No malignancy, n (%) 143 (65.6 %)
Breast cancer, n (%) 70 (32.1 %)
Other malignancy, n (%) 5 (2.3 %)
Family history
Positive for ovarian cancer, n (%) 102 (46.8 %)
Positive for breast cancer, n (%) 140 (64.2 %)
Positive for breast and ovarian cancer, n (%) 76 (34.9 %)
Unknown, n (%) 51 (23.4 %)
RRSOa uptake
Yes, n (%) 190 (87.2 %)
No, n (%) 28 (12.8 %)
Age at RRSOa (n = 186)
Median (range), years 44.5 (28–73)
Mean (standard deviation), years 46.32 (±8.24)
RRMb uptake
Yes, n (%) 107 (49.1 %)
No, n (%) 93 (42.7 %)
Missing, n (%) 18 (8.3 %)
a Risk-reducing salpingo-oophorectomy
b Risk-reducing mastectomy
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No significant increased odds of undergoing a RRSO
were identified if there was a first or a second/third degree
relative with a history of ovarian cancer [OR 0.61; 95 % CI
(0.23–1.62) and OR 1.30; 95 % CI (0.37–4.57) respec-
tively]. This also accounted for women with a first or
second/third degree relative with a history of breast cancer
[OR 0.85; 95 % CI (0.31–2.33) and OR 1.30; 95 % CI
(0.49–3.44) respectively]. Family history of ovarian and/or
breast cancer evaluated altogether also showed no signifi-
cant increased odds for undergoing RRSO [OR 1.10; 95 %
CI (0.44–2.76)].
Discussion
We show that RRSO uptake is high after counseling and
that only few consultations at the gynecologist are needed,
to decide to undergo RRSO.
Secondly, women with a personal medical history of
breast cancer do not seem to be more likely to undergo
RRSO, than those without. This also accounts for women
with a family history of ovarian and/or breast cancer.
Reported RRSO uptake in the literature varies from 10.9
to 75 % [22–34]. In comparison, RRSO uptake in this
Table 2 Number of consultations needed to decide for RRSO relative to personal and family history (n = 190)
Mean ± standard deviation number of consultationsa p valueb
Absent Present
Breast cancer in personal medical history 2.29 ± 3.19 2.90 ± 3.02 0.51
Any malignancy in personal medical historyc 2.35 ± 3.24 2.73 ± 2.93 0.67
RRMd in personal medical history 2.11 ± 2.54 3.10 ± 3.90 0.38
Ovarian cancer in 1st degree relative 2.19 ± 2.80 2.96 ± 3.61 0.02
Ovarian cancer in 2nd or 3rd degree relative 2.30 ± 2.90 3.14 ± 3.88 0.33
Breast cancer in 1st degree relative 3.09 ± 3.82 1.90 ± 2.20 <0.01
Breast cancer in 2nd or 3rd degree relative 2.19 ± 2.46 3.02 ± 4.11 0.06
Statistically significant p values are presented in bold
a While ‘number of consultations’ follows a Poisson distribution, results are deliberately presented in means and standard deviations whereas
medians and ranges (in integer values) would obscure the subtle differences between groups
b Based on the non-parametric Mann–Whitney U test
c Excludes all non-melanoma skin malignancies
d Risk-reducing mastectomy





95 % CIc Multivariabled
ORb
95 % CIc
Breast cancer in personal medical history 91.4 1.86 0.72–4.82 1.38 0.50–3.79
Any malignancy in personal medical historye 92.0 2.09 0.81–5.41 1.60 0.59–4.37
RRMf in personal medical history 94.7 3.59 1.20–10.73 3.66 1.12–11.98
Ovarian cancer in 1st degree relative 84.3 0.52 0.21–1.27 0.61 0.23–1.62
Ovarian cancer in 2nd or 3rd degree relative 90.0 1.27 0.40–4.05 1.30 0.37–4.57
Breast cancer in 1st degree relative 88.8 1.16 0.46–2.91 0.85 0.31–2.33
Breast cancer in 2nd or 3rd degree relative 88.3 1.13 0.46–2.80 1.30 0.49–3.44
Ovarian and breast cancer in 1st, 2nd or 3rd degree
relative
86.8 1.02 0.42–2.47 1.10 0.44–2.76




d Adjusted for mutation status, age, parity and menopausal status
e Excludes all non-melanoma skin malignancies
f Risk-reducing mastectomy
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study is relatively high. An explanation for this difference
is that in most studies, screening for ovarian cancer is
offered as an alternative to undergoing RRSO [23, 26–29,
32–34], even though in the meantime it had sufficiently
been shown that this was not effective in reducing ovarian
cancer mortality [13–19].
It has been published that RRSO uptake is higher in
women with a personal medical history of breast cancer
[22, 23, 27, 29]. But only two studies could support this
with significant results in multivariable analyses [27, 29].
In two other studies, RRSO uptake was even lower in
women with a medical history of breast cancer [28, 32].
In several studies, RRM in personal medical history also
seemed to have an influence, showing positive odds ratios
in univariable analyses [7, 22, 23, 28].
Family history of ovarian and/or breast cancer were
thought to be factors of influence, as some studies conclude
[23, 27, 30, 33], although not all analyses were multivariable
with adjustment for known factors of influence [27, 33].
A limitation of this study is that information bias might
have occurred because of the study design. Although not all
possible factors of influence in the decision making of
undergoing RRSO (i.e. demographic factors) could be
evaluated, for lack of available information. Detailed
information on family history was not present for every
patient, but it was collected as thoroughly as possible by
standardized questioning by the experts.
Our findings are likely influenced by the method of
counseling performed and particularly the fact that
screening was not offered. Therefore, results of this study
may not be extended towards situations where alternative
strategies such as screening are offered. However, our
results do indicate that a protocol based solely on RRSO
counseling, without the alternative option of screening, is
effective in establishing a high uptake of RRSO in women
with an increased lifetime risk of ovarian cancer. This
protocol can be useful in a variety of health-care systems
given that most women who ultimately decide for RRSO
needed 3 or less counseling sessions. We consider a mul-
tidisciplinary approach by a gynecologic oncologist, clin-
ical geneticist and nurse specialist, specialized in familial
cancer care, pivotal in this counseling practice.
Future studies may focus on validating the current
results, as well as investigating other possible factors of
influence (e.g. psychological), possibly within the context
of a qualitative study. Especially the subgroup who needed
[3 consultations in the RRSO decision making process is
of interest with respect to their considerations. Such an
analysis may identify opportunities for improving and
individualizing the counseling practice.
In conclusion, the majority (87.2 %) of the women
carrying a BRCA mutation or having familial susceptibility
to ovarian cancer, who visited our clinic, where screening
is not offered, opted for RRSO. This decision is made
relatively quick; the majority decided after the first con-
sultation with the gynecologist. This approach is therefore
likely to be effective in reducing ovarian cancer related
mortality in this high risk population. Personal medical
history of (breast) cancer was not found to significantly
affect the decision to undergo RRSO, though women who
had undergone RRM were more likely to opt for RRSO.
Also, patients with 1st degree relatives who had breast
cancer needed significantly less consultations to decide for
RRSO.
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